Contact us
Please complete the form below and a member of the ELAHERE®▼ (mirvetuximab soravtansine) team will get back to you.
Please fill in your details below only if you are a UK registered healthcare professional and would like to contact an AbbVie representative.
ELAHERE® as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1
Eligible patients should have FRα tumour status defined as ≥75% viable tumour cells demonstrating moderate (2+) and/or strong (3+) membrane staining by immunohistochemistry.1